Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

3rd Quarter Results

31 Oct 2012 07:00

RNS Number : 9003P
Beximco Pharmaceuticals Ltd
31 October 2012
 



BEXIMCO PHARMACEUTICALS LTD.

 

31st October, 2012

 

Financial Results for the Third Quarter of 2012

 

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its unaudited financial results for the third quarter and nine months ended 30 September 2012. The information set out below has been released to the Dhaka and Chittagong Stock Exchanges in compliance with the requirements from the Bangladesh SEC.

 

 

The accounts can be viewed at the Company's website:

www.beximcopharma.com 

 

 

For further enquiries please contact:

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

 

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; +880 2 8618220-1, Ext 10140

 

Libertas Capital Corporate Finance

Thilo Hoffmann

Tel: +44 (0)20 7569 9650

 

FTI Consulting

Simon Conway / Susan Stuart / Victoria Foster-Mitchell

Tel: +44 (0)20 7269 7169

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,500 staff.

 

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

 

 

 

Beximco Pharmaceuticals Ltd.

Statement of Financial Position (Un-audited)

As at September 30, 2012

 

 

Taka in thousand

As at

As at

September 30, 2012

December 31, 2011

ASSETS

Non-Current Assets

16,336,036

15,884,878

Property, Plant and Equipment- Carrying Value

16,176,462

15,745,493

Intangible Assets

156,123

135,934

Investment in Shares

3,451

3,451

Current Assets

7,945,056

7,148,463

Inventories

2,324,252

2,291,845

Spares & Supplies

369,494

325,881

Accounts Receivable

1,244,678

978,224

Loans, Advances and Deposits

919,476

840,321

Short Term Investment

2,555,974

2,193,424

Cash and Cash Equivalents

531,182

518,768

TOTAL ASSETS

24,281,092

23,033,341

EQUITY AND LIABILITIES

Shareholders' Equity

18,117,658

17,128,129

Issued Share Capital

3,046,390

2,517,678

Share Premium

5,269,475

5,269,475

Excess of Issue Price over Face Value of GDRs

1,689,637

1,689,637

Capital Reserve on Merger

294,951

294,951

Revaluation Surplus

1,405,911

1,466,603

Retained Earnings

6,411,294

5,889,785

Non-Current Liabilities

3,283,809

3,257,051

Long Term Borrowings-Net off Current Maturity (Secured)

1,629,189

1,890,075

Liability for Gratuity & WPPF

487,111

403,599

Deferred Tax Liability

1,167,509

963,377

Current Liabilities and Provisions

2,879,625

2,648,161

Short Term Borrowings

1,663,278

1,642,216

Long Term Borrowings-Current Maturity

553,342

363,744

Creditors and Other Payables

443,833

523,798

Accrued Expenses

93,026

101,560

Dividend Payable

1,229

1,361

Income Tax Payable

124,917

15,482

TOTAL EQUITY AND LIABILITIES

24,281,092

23,033,341

 

 

 

Beximco Pharmaceuticals Ltd.

Statement of Comprehensive Income (Un-audited)

For the Third Quarter Ended September 30, 2012

 

 

Taka in thousand

January - September 2012

January - September 2011

July - September 2012

July- September 2011

Net Sales Revenue

6,774,426

5,788,892

2,428,072

2,146,599

Cost of Goods Sold

(3,585,805)

(3,000,217)

(1,218,262)

(1,079,306)

Gross Profit

3,188,621

2,788,675

1,209,810

1,067,293

Operating Expenses

(1,528,606)

(1,264,209)

(562,306)

(461,087)

Administrative Expenses

(238,693)

(194,746)

(87,811)

(82,844)

Selling, Marketing and Distribution Expenses

 

(1,289,913)

 

(1,069,463)

 

(474,495)

 

(378,243)

Profit From Operations

1,660,015

1,524,466

647,504

606,206

Other Income

319,963

230,076

112,640

79,169

Finance Cost

(479,991)

(412,489)

(150,266)

(146,098)

Profit Before Contribution to WPPF

1,499,987

1,342,053

609,878

539,277

Contribution to WPPF

(71,428)

(63,907)

(29,042)

(25,680)

Profit Before Tax

1,428,559

1,278,146

580,836

513,597

Income Tax Expense

(393,877)

(310,141)

(159,559)

(116,835)

Profit After Tax

1,034,682

968,005

421,277

396,762

Other Comprehensive Income

-

-

-

-

Total Comprehensive Income

1,034,682

968,005

421,277

396,762

EPS / Restated EPS (2011) Tk.

3.40

3.18

1.38

1.30

Number of Shares Used to Compute EPS

304,639,050

304,639,050

304,639,050

304,639,050

 

 

 

Beximco Pharmaceuticals Ltd.

Statement of Changes in Equity (Un-audited)

For the Period Ended September 30, 2012

 

 

For the Period Ended September 30, 2012

Taka in thousand

Share Capital

Share Premium

Excess of Issue Price over Face Value of GDRs

Capital Reserve on Merger

Revaluation Surplus

Retained Earnings

Total

Balance on January 01, 2012

2,517,678

5,269,475

1,689,637

294,951

1,466,603

5,889,785

17,128,129

Total Comprehensive Income

-

-

-

-

-

1,034,682

1,034,682

Stock Dividend for 2011

528,712

-

-

-

-

(528,712)

-

Adjustment for Depreciation on Revalued Assets

-

-

-

-

(15,539)

15,539

-

Adjustment for Deferred Tax on Revalued Assets

-

-

-

-

(45,153)

-

(45,153)

Balance as on September 30, 2012

3,046,390

5,269,475

1,689,637

294,951

1,405,911

6,411,294

18,117,658

Net Asset Value (NAV) per Share

Tk. 59.47

 

 

For the Period Ended September 30, 2011

Taka '000

Share Capital

Share Premium

Excess of Issue Price over Face Value of GDRs

Capital Reserve on Merger

Revaluation Surplus

Retained Earnings

Total

Balance on January 01, 2011

2,098,065

5,269,475

1,689,637

294,951

1,534,646

5,087,313

15,974,087

Total Comprehensive Income

-

-

-

-

-

968,005

968,005

Stock Dividend for 2010

419,613

-

-

-

-

(419,613)

-

Adjustment for Depreciation on Revalued Assets

-

-

-

-

(17,670)

17,670

-

Adjustment for Deferred Tax on Revalued Assets

-

-

-

-

(51,046)

-

(51,046)

Balance as on September 30, 2011

2,517,678

5,269,475

1,689,637

294,951

1,465,930

5,653,375

16,891,046

Net Asset Value (NAV) per Share

Tk. 67.09

 

 

 

Beximco Pharmaceuticals Ltd.

Statement of Cash Flows (Un-audited)

For the Period Ended September 30, 2012

 

 

Taka in thousand

January -

January -

July -

July -

September

September

September

September

2012

2011

2012

2011

Cash Flows from Operating Activities :

Cash Receipts from Customers and Others

6,508,721

5,618,003

2,207,857

2,049,564

Cash Paid to Suppliers and Employees

(4,903,698)

(4,012,833)

(1,819,956)

(1,370,617)

Cash Generated from Operations

1,605,023

1,605,170

387,901

678,947

Interest Paid

(479,991)

(412,489)

(150,266)

(146,098)

Interest Received

316,383

229,917

112,347

79,170

Income Tax Paid

(125,462)

(113,183)

(36,815)

(40,832)

Net Cash Generated from Operating Activities

1,315,953

1,309,415

313,167

571,187

Cash Flows from Investing Activities :

Acquisition of Property, Plant and Equipment

(864,588)

(953,113)

(160,263)

(419,319)

Intangible Assets

(30,859)

(77,106)

(9,652)

(43,125)

Disposal of Property, Plant and Equipment

4,816

-

336

-

Short Term Investment

(362,550)

(1,619,941)

(9,355)

(1,521,299)

Net Cash Used in Investing Activities

(1,253,181)

(2,650,160)

(178,934)

(1,983,743)

Cash Flows from Financing Activities :

Net Increase/(Decrease) in Long Term Borrowings

 

(71,288)

 

(65,883)

 

(16,426)

 

11,677

Net Increase/(Decrease) in Short Term Borrowings

 

21,062

 

20,712

 

(98,232)

 

1,269

Ordinary Share Dividend

(132)

(444)

-

(313)

Net Cash Generated from Financing Activities

 

(50,358)

 

(45,615)

 

(114,658)

 

12,633

Increase/(Decrease) in Cash and Cash Equivalents

 

12,414

 

(1,386,360)

 

19,575

 

(1,399,923)

Cash and Cash Equivalents at Beginning of Period

 

518,768

 

1,471,448

 

511,607

 

1,485,011

Cash and Cash Equivalents at End of Period

 

531,182

 

85,088

 

531,182

 

85,088

Net Operating Cash Flow Per Share

Tk

 

4.32

 

5.20

 

1.03

 

2.27

 

 

The detail of the published Interim Financial Statements is available at the Company's website:

www.beximcopharma.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
QRTGMMFGNGLGZZM
Date   Source Headline
5th Mar 20269:13 amRNSUpdate on Writ Petitions
28th Jan 20262:01 pmRNSOrder re Extension to Publish Financial Results
2nd Jan 20267:30 amRNSSuspension - Beximco Pharmaceuticals PLC
2nd Jan 20267:30 amRNSSuspension - Beximco Pharmaceuticals PLC
19th Dec 202511:00 amRNSDelay in Results & Temporary Suspension
19th Dec 202511:00 amRNSDelay in Results & Temporary Suspension
13th Nov 20254:00 pmRNSRequest of Extension to Publish Q1 Results
4th Nov 20257:00 amRNSChange of Name to Beximco Pharmaceuticals PLC.
27th Oct 20253:53 pmRNSRequest of Extension to Publish Financial Results
24th Oct 20257:00 amRNS-RAffordable treatment option for cystic fibrosis
15th Sep 20251:17 pmRNSFurther update on BSEC Order
21st May 20253:18 pmRNSUpdate on BSEC Order
28th Apr 20257:00 amRNSRequest of Extension to Publish Q3 Results
21st Mar 20253:51 pmRNSResponse to media reports and update on BSEC order
6th Mar 20257:00 amRNSUpdate on BSEC order
30th Jan 20252:59 pmRNSPayment of Cash Dividend
29th Jan 20257:01 amRNSBoard Changes
29th Jan 20257:00 amRNSHalf Year Results 2024-25
14th Jan 202511:24 amRNSBoard of Directors
30th Dec 20247:00 amRNSAnnual General Meeting Statement
19th Nov 20247:00 amRNSAGM Notification
14th Nov 20247:00 amRNSFinancial Results for the First Quarter
12th Nov 202410:00 amRNSRestoration - Beximco Pharmaceuticals Limited
12th Nov 202410:00 amRNSUpdate on Interim Order Supreme Court decision
11th Nov 202411:01 amRNSFurther re the Temporary Suspension of Trading
11th Nov 20247:30 amRNSSuspension - Beximco Pharmaceuticals Limited
7th Nov 20247:00 amRNSResults for the year ended 30 June 2024
29th Oct 20247:00 amRNSNotification of Preliminary Results and AGM
28th Oct 20242:35 pmRNSUpdate on Writ Petition and Interim Order
2nd Oct 20247:00 amRNSUpdate on Writ Petition and Interim Order
30th Sep 20247:06 amRNSClarification on Writ Petition
6th Sep 20242:17 pmRNSUpdate regarding Vice-Chairman, Salman Rahman
3rd Sep 20241:45 pmRNSCorrection and Clarification of Press Commentary
15th Aug 20247:00 amRNSStatement regarding Vice-Chairman, Salman Rahman
13th Aug 20247:00 amRNSStatement on political and business situation
30th Apr 20247:00 amRNSQ3 Financial Results
4th Mar 20247:00 amRNSAppointment of Managing Director
30th Jan 20247:00 amRNSHalf Year Results 2023-24
25th Jan 20249:53 amRNSPayment of Cash Dividend
11th Jan 202411:44 amRNSBoard Change
28th Dec 20239:40 amRNSAGM Statement
6th Nov 202312:17 pmRNSNotice of AGM
6th Nov 20237:00 amRNSFinancial Results for the First Quarter
1st Nov 20237:00 amRNSResults for the year ended 30 June 2023
20th Oct 20237:00 amRNSNotification of Preliminary Results and AGM
11th Sep 202310:17 amRNSClarification on Press Report
31st Aug 20233:51 pmRNSRe-appointment of Independent Director
2nd May 20237:00 amRNSQ3 Financial Results
11th Apr 20233:59 pmRNSHoldings in Company
31st Mar 202311:03 amRNSHoldings in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.